Literature DB >> 27067327

Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.

Adam Belley1, David Lalonde Seguin2, Francis Arhin2, Greg Moeck2.   

Abstract

Antibacterial agents that kill nondividing bacteria may be of utility in treating persistent infections. Oritavancin and dalbavancin are bactericidal lipoglycopeptides that are approved for acute bacterial skin and skin structure infections in adults caused by susceptible Gram-positive pathogens. Using time-kill methodology, we demonstrate that oritavancin exerts bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) isolates that are maintained in a nondividing state in vitro, whereas dalbavancin and the glycopeptide vancomycin do not.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27067327      PMCID： PMC4914647          DOI： 10.1128/AAC.00169-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Bactericidal activity and resistance development profiling of dalbavancin.

Authors:  Beth P Goldstein; Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Authors:  Adam Belley; Geoffrey A McKay; Francis F Arhin; Ingrid Sarmiento; Sylvain Beaulieu; Ibthihal Fadhil; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

Review 3.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

4.  Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.

Authors:  Daniela Baldoni; Ulrika Furustrand Tafin; Sandrine Aeppli; Eline Angevaare; Alessandra Oliva; Manuel Haschke; Werner Zimmerli; Andrej Trampuz
Journal:  Int J Antimicrob Agents       Date:  2013-07-20       Impact factor: 5.283

Review 5.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra; Richard E Lee
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

6.  In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

Authors:  Sara Lopez; Corinne Hackbarth; Gabriella Romanò; Joaquim Trias; Daniela Jabes; Beth P Goldstein
Journal:  J Antimicrob Chemother       Date:  2005-03       Impact factor: 5.790

7.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.

Authors:  Carmela T M Mascio; Jeff D Alder; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

9.  Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Authors:  Adam Belley; Eve Neesham-Grenon; Geoffrey McKay; Francis F Arhin; Robert Harris; Terry Beveridge; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

10.  Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

Authors:  Adam Belley; Eve Neesham-Grenon; Francis F Arhin; Geoffrey A McKay; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191
  10 in total
  6 in total

1.  Effects of Microplate Type and Broth Additives on Microdilution MIC Susceptibility Assays.

Authors:  Angela Kavanagh; Soumya Ramu; Yujing Gong; Matthew A Cooper; Mark A T Blaskovich
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Antimicrobial Activity of the Quinoline Derivative HT61 against Staphylococcus aureus Biofilms.

Authors:  R N Allan; J S Webb; C J Frapwell; P J Skipp; R P Howlin; E M Angus; Y Hu; A R M Coates
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus.

Authors:  Andrew D Berti; Lauren T Harven; Victoria Bingley
Journal:  Antibiotics (Basel)       Date:  2020-11-08

4.  Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics.

Authors:  Christian Eckmann; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

5.  Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties.

Authors:  Randall K Hoover; Martin Krsak; Kyle C Molina; Kairav Shah; Mark Redell
Journal:  Open Forum Infect Dis       Date:  2022-03-23       Impact factor: 3.835

6.  Novel Miniature Membrane Active Lipopeptidomimetics against Planktonic and Biofilm Embedded Methicillin-Resistant Staphylococcus aureus.

Authors:  Seema Joshi; Sana Mumtaz; Jyotsna Singh; Santosh Pasha; Kasturi Mukhopadhyay
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.